|
|
|
Press
Releases
|
|
International and Local Recognition for Singaporean Biotech Start-up – Curiox Biosystems
|
18 January 2010
Singapore-based Curiox Biosystems recently became the first Asian start-up company ever to be featured at
LabAutomation's prestigious Innovation AveNEW, a program serving to highlight the
industry's most innovative emerging laboratory technologies. Curiox shall be presented as one of eight elite start-ups, chosen from a pool of worldwide participants, at the Innovation AveNEW booth from January 25th to 27th.
LabAutomation is a premier industry event, known to be the world's largest conference and exhibition focused on laboratory products and technologies in Life Sciences. The international recognition received at LabAutomation2010 is a great achievement for young start-up Curiox, which was selected by a panel of international industry experts from the Association for Laboratory Automation (ALA). Only a select few start-up companies are chosen for the Innovation AveNEW program each year.
The annual Innovation AveNEW program is currently in its fourth year, and serves to afford emerging, start-up companies the opportunity to actively engage and participate in a world-class event by offering the Innovation AveNEW winners free exhibit space and travel. The program gives participants access to more than 4,000 purchasing influencers and decision-makers from more than 40 countries in laboratory automation market.
Curiox shall be maximizing the exposure received at LabAutomation2010 by highlighting its latest product, the DropArray™ Accelerator HT200, at the event. Presently, DropArray™ HT200 is being assessed by key market leaders in biotech and pharma.
Locally, Curiox has obtained further validation of DropArray™
technology's value proposition by closing a second round of financing with a group of corporate, angel and institutional investors. This second closing represents a significant accomplishment for Curiox, as a majority of the angel investors are veterans from the bioinstrumentation industry.
This second tranche of money shall allow Curiox to direct more funds to marketing for penetration into the United States and European markets.
"Curiox has managed to secure international and local excitement, with its revolutionary DropArray technology, in less than 2 years. This represents a significant milestone for Singapore, and is proof that Singapore-based biotech companies are able to compete on a global scale.
This early achievement for Curiox was possible due to the ecosystem provided by Exploit Technologies and NUS Enterprise; as well as, the network and financial support offered by Nanostart
Asia," says Curiox's CEO, Dr Namyong Kim.
For now, Curiox's strategy is to establish itself in the research and screening markets with the DropArray™ HT200. Eventually, Curiox hopes to venture into the diagnostic and point-of-care markets, with its platform DropArray™ technology.
About Curiox Biosystems Pte Ltd:
Curiox Biosystems has a vision to accelerate the progress of life sciences and drug discovery through better miniaturization. Curiox is a bioinstrumentation company enabling the miniaturization of bioassays for researchers working in life sciences, drug discovery, and diagnostics.
Curiox's patent-pending miniaturization platform, DropArray™, provides up to 25 times savings in sample and reagent consumption, and up to 60 % reduction in assay time. The company is a spin-off from Institute of Bioengineering and Nanotechnology (IBN) backed primarily by Nanostart and Exploit Technologies, the commercializing arm of
Singapore's Agency for Science, Technology and Research (A*STAR). For further information, please visit www.curiox.com.
For more information, Kindly contact:
Nicole Soo
nicole@curio.com
180 Ang Mo Kio Avenue 8
Block Q, Unit # 501
Singapore 569830
Singapore
|
|
|
กก
|
|
|
